ClinicalTrials.gg
Not yet recruitingNCT06798506Updated Jan 29, 2025

Real-world Patient-reported Outcome of Sacituzumab Govitecan in Chinese Metastatic Triple-negative Breast Cancer

An observational study in TNBC - Triple-Negative Breast Cancer, sponsored by Fudan University. Not yet recruiting at 1 site in China. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-01-29.

Sponsored by Fudan University · Observational

How we know · 2 judgments

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
300
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 65 studies in Triple Negative Breast Neoplasms by Fudan University — 35 open to participants now, 39 under way, 12 of them phase 3. Triple Negative Breast Neoplasms · Fudan University.

Started
2025
with 6 others
Observational
3 of 65
3 open now
Primary completion
2027-01
later than 18 of 38 live
Registered
51st of 65
by date

Among the 65 studies in Triple Negative Breast Neoplasms by Fudan University, this one is one of 7 that started in 2025, is one of 3 observational ones, reaches primary completion later than 18 of the 38 other live ones, and was the 51st registered.

Triple Negative Breast Neoplasms

1,219 studies on the registry are indexed under Triple Negative Breast Neoplasms; 441 are open to participants now.

Browse Triple Negative Breast Neoplasms studies →

Open to participants now

35 of the 65 studies in Triple Negative Breast Neoplasms by Fudan University are open now, in 1 country. Recruiting first, the newest first:

30 more — sign in →

By country, each count listing its studies:

All 35 open studies →

Where they have run

Who these studies take

Of the 329 Triple Negative Breast Neoplasms studies recruiting now, 229 (70%) set no upper age limit and 85 (26%) stop at 75 or younger; 12 take children under 18; 6 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 65 studies in Triple Negative Breast Neoplasms by Fudan University, or all of them as a file.
02

Study summary

The aim of this trial is to explore the real-world patient-reported health-related quality of life (HRQOL), functioning, symptoms and symptom tolerability of sacituzumab govitecan or chemotherapy of the physician's choice for Chinese mTNBC patients. Evaluation of HRQOL and functioning using the EORTC QLQ-C30 and QLQ-BR45 questionnaires, including change from baseline and time to deterioration in each scale or item. Treatment-related symptoms and tolerability were assessed using the Patient-Reported Outcomes of the PRO-CTCAE and PGI-TT questionnaires.

03

Conditions studied

  • TNBC - Triple-Negative Breast Cancer

Keywords

  • Sacituzumab Govitecan
  • chemotherapy
  • metastatic breast cancer
  • TNBC
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients have been diagnosed with metastatic triple-negative breast cancer (mTNBC). ER, PgR, and HER2 status were determined locally by immunohistochemistry (IHC) of patients' primary or metastatic tumor sections.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients aged over 18 years old.
  2. Patients have been diagnosed with triple-negative breast cancer (mTNBC). ER, PgR, and status were determined locally by immunohistochemistry (IHC) of patients' primary or metastatic tumor sections. ER-negative and PgR-negative status was defined as≤1% staining in the nuclei by IHC. HER2-negative status was defined by IHC staining 0 to 1+ or fluorescence in situ hybridization ratio \<2.0 if IHC 2+ or IHC not performed.
  3. The metastatic disease was confirmed by clinical, imaging, histological, or cytological measures, including unresectable locally advanced breast cancer, de novo stage IV breast cancer, and recurrent metastatic breast cancer.
  4. Patients who have received at least 1 prior regimen in the metastatic setting.
  5. Plan to receive or has received sacituzumab govitecan monotherapy or chemotherapy of the physician's choice.
  6. Available medical history.
  7. All patients can provide an before enrolment and data collection.

Exclusion criteria

Exclusion Criteria:

  1. If participating in any controlled clinical trial, the subject cannot take part in this study.
  2. overexpression or gene amplification, ie, immunohistochemistry (IHC) 3+ or fluorescence in situ hybridisation (FISH)+, where appropriate.
  3. Pregnancy and lactation.
  4. Severe hepatic impairment.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
300 participants (estimated)
Patient registry
No

Groups and cohorts

  • Sacituzumab Govitecan cohort
  • Chemotherapy of the physician's choice cohort

This study also gives Sacituzumab govitecanStudies of Sacituzumab govitecanSacituzumab govitecan pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.. No intervention listed here names it: that was found by reading the record.

06

What researchers measure

Primary outcomes

  1. Patient-reported HRQOL

    Patient-reported health-related quality of life (HRQOL) evaluated by EORTC QLQ-C30 questionnaires

    Time frame: 6 weeks

Secondary outcomes

  1. Patient-reported functioning

    Patient-reported functioning evaluated by QLQ-BR45 questionnaires.

    Time frame: 6 weeks

  2. Patient-reported symptoms

    Treatment-related symptoms were assessed using the Patient-Reported Outcomes of the PRO-CTCAE.

    Time frame: 6 weeks

  3. Patient-reported tolerability

    Treatment-related tolerability were assessed using the Patient-Reported Outcomes of the PGI-TT questionnaires.

    Time frame: 6 weeks

  4. PFS

    Progression free survival

    Time frame: 6 weeks

  5. ORR

    Overall Response Rate

    Time frame: 6 weeks

  6. CBR

    Clinical benefit Rates

    Time frame: 6 weeks

  7. OS

    Overall Survival

    Time frame: 6 weeks

  8. Safety

    Number of participants with treatment-related adverse events as assessed by CTCAE v5.0

    Time frame: 6 weeks

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Feb 2025; primary completion for Jan 2027, 23 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 18, 2024
First posted
Jan 29, 2025
StartEst.
Feb 15, 2025
Primary completionEst.
Jan 15, 2027
CompletionEst.
May 15, 2027
Last update
Jan 29, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 29, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06798506
Lead sponsor
Fudan University
Responsible party
Biyun Wang, MD (Professor, Fudan University) — Principal investigator
First posted
Jan 29, 2025
Start date
Feb 15, 2025 (estimated)
Primary completion
Jan 15, 2027 (estimated)
Completion
May 15, 2027 (estimated)
Last update
Jan 29, 2025

Study contacts

Biyun Wang, Professor
Contact
pro_wangbiyun@163.com
+86 13701748410

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion